<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List href="./Page2_files/filelist.xml">
<link rel=Edit-Time-Data href="./Page2_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title> </title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>jennifer</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>jennifer</o:LastAuthor>
  <o:Revision>36</o:Revision>
  <o:TotalTime>367</o:TotalTime>
  <o:Created>2006-10-30T13:45:00Z</o:Created>
  <o:LastSaved>2006-11-03T14:42:00Z</o:LastSaved>
  <o:Pages>3</o:Pages>
  <o:Words>1149</o:Words>
  <o:Characters>6550</o:Characters>
  <o:Company>EMBL-EBI</o:Company>
  <o:Lines>54</o:Lines>
  <o:Paragraphs>13</o:Paragraphs>
  <o:CharactersWithSpaces>8043</o:CharactersWithSpaces>
  <o:Version>9.6926</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>75</w:Zoom>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1 -369098753 63 0 4129023 0;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1 -369098753 63 0 4129023 0;}
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:16.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Arial Unicode MS";
	mso-font-kerning:16.0pt;}
h2
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:14.0pt;
	font-family:Arial;
	mso-fareast-font-family:"Arial Unicode MS";
	font-style:italic;}
h3
	{mso-style-next:Normal;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:12.0pt;
	font-family:"Times New Roman";
	color:navy;
	font-weight:normal;
	font-style:italic;}
h4
	{mso-style-next:Normal;
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:12.0pt;
	font-family:"Times New Roman";
	color:maroon;
	font-weight:normal;
	font-style:italic;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:36.0pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
@list l0
	{mso-list-id:498231737;
	mso-list-type:hybrid;
	mso-list-template-ids:1727273840 1696212148 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:46.35pt;
	mso-level-number-position:left;
	margin-left:46.2pt;
	text-indent:-17.85pt;
	mso-ansi-font-size:8.0pt;
	font-family:Symbol;}
@list l1
	{mso-list-id:853300835;
	mso-list-type:hybrid;
	mso-list-template-ids:-1797122602 1696212148 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:46.35pt;
	mso-level-number-position:left;
	margin-left:46.2pt;
	text-indent:-17.85pt;
	mso-ansi-font-size:8.0pt;
	font-family:Symbol;}
@list l2
	{mso-list-id:1831363692;
	mso-list-type:hybrid;
	mso-list-template-ids:-1058622560 1696212148 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l2:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:46.35pt;
	mso-level-number-position:left;
	margin-left:46.2pt;
	text-indent:-17.85pt;
	mso-ansi-font-size:8.0pt;
	font-family:Symbol;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1033"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoNormal><a href="http://www.ebi.ac.uk/interpro/"
title="To the InterPro database"><span style='text-decoration:none;text-underline:
none'><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:139.5pt;
 height:45pt'>
 <v:imagedata src="./Page2_files/image001.png" o:title="InterPro"/>
</v:shape><![endif]--><![if !vml]><img border=0 width=186 height=60
src="./Page2_files/image002.jpg" v:shapes="_x0000_i1025"><![endif]></span></a></p>

<h1 align=center style='text-align:center'><span style='font-size:28.0pt;
mso-bidi-font-size:16.0pt;color:maroon'>Fibrinogen<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='font-size:14.0pt;mso-bidi-font-size:16.0pt;color:maroon'>Wound
Healing<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<table border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;
 mso-padding-alt:0cm 5.4pt 0cm 5.4pt'>
 <tr>
  <td width=191 valign=top style='width:143.1pt;background:#CCCCCC;padding:
  0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoBodyText align=center style='text-align:center'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  <p class=MsoBodyText align=center style='text-align:center'><!--[if gte vml 1]><v:shape
   id="_x0000_i1026" type="#_x0000_t75" style='width:138.75pt;height:161.25pt'>
   <v:imagedata src="./Page2_files/image003.jpg" o:title="Blood_cell Clot_Rochester_Uni"/>
  </v:shape><![endif]--><![if !vml]><img border=0 width=185 height=215
  src="./Page2_files/image004.jpg" v:shapes="_x0000_i1026"><![endif]></p>
  <p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  </td>
  <td width=405 valign=top style='width:304.1pt;background:#FFA7A7;padding:
  0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoBodyText align=left style='text-align:left'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  <p class=MsoBodyText align=left style='text-align:left'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  <p class=MsoBodyText align=left style='text-align:left'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  <p class=MsoBodyText align=left style='text-align:left'><u>Figure 4</u>.<b><span
  style="mso-spacerun: yes">  </span>Blood Clot:</b><span style="mso-spacerun:
  yes">  </span>Fibrin polymers appear as strands surrounding red blood cells.</p>
  <p class=MsoBodyText align=left style='text-align:left'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  <p class=MsoBodyText align=left style='text-align:left'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  <p class=MsoBodyText align=left style='text-align:left'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-indent:36.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>The mechanical
properties of a blood clot are essential for proper haemostasis and wound
healing.<span style="mso-spacerun: yes">  </span>A blot clot needs to be strong
in order to withstand physical and chemical abrasion, but it also needs to be
elastic enough not to crack or split with body movement.<span
style="mso-spacerun: yes">  </span>In addition, it must also be digestible by
lytic enzymes; otherwise, thrombosis could occur as the clot breaks down, which
is one of the most common causes of heart attacks and stroke.<span
style="mso-spacerun: yes">  </span>If thrombosis occurs in an artery, the
tissues supplied by that artery would become necrotic, which could lead to
myocardial infarction (heart attack) if the thrombosis is in a coronary artery.<span
style="mso-spacerun: yes">  </span>If the thrombosis occurs in a vein, the
tissues draining into that vein would become swollen and inflamed, leading to
pulmonary embolism if the clot reaches the heart.<span style="mso-spacerun:
yes">  </span>By contrast, if the clot is insufficient in size or rigidity,
then haemorrhaging can occur.</p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>The characteristics
of a blood clot depend upon several factors, especially the structure of the
fibrin polymer, including the thickness of the fibres and number of branch
points, as well as how permeable it is, which in turn affects its accessibility
to incoming repair cells.<span style="mso-spacerun: yes">  </span>Its
elasticity is due to the ability of long fibrin fibres to bend.<span
style="mso-spacerun: yes">  </span>In addition, the cross-linking of fibrin
polymers renders a clot much stiffer and resistant to being broken down, but
this stiffness must be finely controlled.<span style="mso-spacerun: yes"> 
</span></p>

<p class=MsoBodyTextIndent>There are different splice variant of fibrinogen,
which can result in low- and high-molecular weight variants, each with their
own clotting rate and fibrin polymer characteristics.<span style="mso-spacerun:
yes">  </span>These naturally occurring variants can modify the ability of
endothelial cells to develop new blood cells (angiogenesis) within the fibrin
matrix.<span style="mso-spacerun: yes">  </span>Therefore, the level of the
different variants is an important factor in angiogenesis.<span
style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h4><b>Platelet aggregation<o:p></o:p></b></h4>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>The binding of
fibrinogen to platelets is an important part of wound healing by aggregating to
form a haemostatic plug and by stimulating the activation of blood coagulation
factors.<span style="mso-spacerun: yes">  </span>Platelets are one of the main
components of blood and play an important role in preventing blood loss through
cell adhesion and aggregation to help form a blood clot.<span
style="mso-spacerun: yes">  </span>They are also involved in the release of
chemical platelet factors into blood.<span style="mso-spacerun: yes"> 
</span>Platelet activation causes them to change their shape, allowing them to
stick to and build up on vessel walls, forming a dense plug that is held
together by fibrin.<span style="mso-spacerun: yes">  </span>Fibrinogen binds to
the integrin receptors, <span style='font-family:Symbol'>a</span>IIb<span
style='font-family:Symbol'>b</span>3, on activated platelets, one receptor at
each end of the fibrinogen molecule, thereby acting as a bridge to link
platelets together in order to bring about platelet aggregation.<span
style="mso-spacerun: yes">  </span>The mass of fibrin fibrils and platelets can
entangle blood cells and plasma, helping to increase the mass of the blood clot
at the site of damage. </p>

<p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h4><b>Other interactions<o:p></o:p></b></h4>

<p class=MsoBodyTextIndent>In addition to forming fibrous clots and acting to
aggregate platelets, fibrinogen is involved in other intermolecular
interactions through its binding to various proteins and cells.<span
style="mso-spacerun: yes">  </span>Fibrin can interact with several cell types,
including endothelial cells, smooth muscle cells, fibroblasts, leukocytes and
keratinocytes.<span style="mso-spacerun: yes">  </span>Fibrin can bind to and
accumulate the cells required for the inflammatory response and for tissue
repair at the site of damage.</p>

<p class=MsoBodyTextIndent>In addition, fibrin can bind to several different
proteins, including fibronectin, albumin, thrombospondin, von Willebrand
factor, fibrulin, fibroblast growth factor-2, vascular endothelial growth
factor, interleukin-1.<span style="mso-spacerun: yes">  </span>Binding of
fibrin to these proteins often results in a change to the structure and
properties of the blood clot.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoBodyTextIndent style='margin-left:46.2pt;text-indent:-17.85pt;
mso-list:l1 level1 lfo2;tab-stops:list 46.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><b><i><span style='color:maroon'>Fibronectin</span></i></b><i><span
style='color:maroon'> </span></i>is found in blood and connective tissue, and
is involved in cell adhesion and wound healing.<span style="mso-spacerun:
yes">  </span>Fibronectin can be cross-linked to fibrin, affecting clot size
and density.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoBodyTextIndent style='margin-left:46.2pt;text-indent:-17.85pt;
mso-list:l1 level1 lfo2;tab-stops:list 46.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><b><i><span style='color:maroon'>Albumin</span></i> </b>is
a blood protein.<span style="mso-spacerun: yes">  </span>Its binding to fibrin
affects the lateral aggregation of fibrin, altering the thickness of the fibrin
fibre.</p>

<p class=MsoBodyTextIndent style='margin-left:46.2pt;text-indent:-17.85pt;
mso-list:l1 level1 lfo2;tab-stops:list 46.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><b><i><span style='color:maroon'>Thrombospondin</span></i></b>
is released from the alpha-granules of activated platelets, and is involved in
platelet aggregation.<span style="mso-spacerun: yes">  </span>It acts by
stabilising the interactions between fibrin and the integrins receptors on
platelets.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoBodyTextIndent style='margin-left:46.2pt;text-indent:-17.85pt;
mso-list:l1 level1 lfo2;tab-stops:list 46.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><b><i><span style='color:maroon'>Von Willebrand factor</span></i></b>
is a blood protein involved in platelet adhesion.<span style="mso-spacerun:
yes">  </span>It can be cross-linked to fibrin through the action of factor
XIIIa, and may be important in forming a fibrin-platelet blood clot.</p>

<p class=MsoBodyTextIndent style='margin-left:46.2pt;text-indent:-17.85pt;
mso-list:l1 level1 lfo2;tab-stops:list 46.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><b><i><span style='color:maroon'>Fibrulin</span></i></b>
is an extracellular matrix protein found in blood that can promote platelet
adhesion to the extracellular matrix.<span style="mso-spacerun: yes"> 
</span>Its binding to fibrin may promote platelet adhesion. </p>

<p class=MsoBodyTextIndent style='margin-left:46.2pt;text-indent:-17.85pt;
mso-list:l1 level1 lfo2;tab-stops:list 46.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]>Binding of fibrin to <b><i><span style='color:maroon'>fibroblast
growth factor-2</span></i></b>, <b><i><span style='color:maroon'>vascular
endothelial growth factor</span></i></b>, and <b><i><span style='color:maroon'>interleukin-1</span></i></b>
helps localise these proteins to the site of tissue damage, in order to promote
vascular cell responses needed for wound healing and to repair blood vessels. </p>

<p class=MsoBodyTextIndent style='text-indent:0cm'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h4><b>Hyaluronic acid and wound healing<o:p></o:p></b></h4>

<p class=MsoBodyTextIndent>Hyaluronic acid (HA) is a component of the wound
extracellular matrix.<span style="mso-spacerun: yes">  </span>HA binds to
fibrin, the fibrin matrix helping to organise a HA matrix, which is important
for subsequent wound healing.<span style="mso-spacerun: yes">  </span>HA could
also have a regulatory role in the control of fibrin degradation and
polymerisation, thereby altering the structure of the fibrin polymer gel.<span
style="mso-spacerun: yes">  </span>The HA-fibrin matrix increases the
permeability of the clot and may act as a scaffold through which cells can
migrate, either releasing trapped cells or providing passage for incoming cells
involved in tissue repair.<span style="mso-spacerun: yes">  </span>As cells
migrate into the wound for repair, the HA-fibrin matrix breaks down with the
help of hyaluronidase and plasmin, becoming replaced by a matrix formed from
collagen and glycosaminoglycans.<span style="mso-spacerun: yes">  </span>The
degradation products of both fibrin and HA are important for the regulation of
the inflammatory response and for blood vessel repair.</p>

<p class=MsoBodyTextIndent style='text-indent:0cm'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='font-size:14.0pt;mso-bidi-font-size:16.0pt;color:maroon'>Fibrinolysis,
Dissolving the Clot<o:p></o:p></span></h1>

<p class=MsoNormal style='text-align:justify'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>As
damaged tissue is repaired, the fibrin clot mass must be dissolved in order to
maintain the fluidity of blood.<span style="mso-spacerun: yes">  </span>Plasmin
degrades fibrin within clots.<span style="mso-spacerun: yes">  </span>Plasmin
exists in blood as the zymogen plasminogen, which is converted to active
plasmin by the proteolytic action of tissue-specific or urokinase-type
plasminogen activators.<span style="mso-spacerun: yes">  </span>Plasmin cleaves
fibrin molecules within a clot at specific lysine residues (see Figure 2,
previous page): one in each of the A<span style='font-family:Symbol'>a</span>
protuberances, and the others within the coiled coil regions of A<span
style='font-family:Symbol'>a</span>, B<span style='font-family:Symbol'>b</span>
and <span style='font-family:Symbol'>g</span>.<span style="mso-spacerun: yes"> 
</span>These cleavage reactions break the molecule into five pieces, two A<span
style='font-family:Symbol'>a</span> protuberances, two end pieces each
containing a D domain, and a central portion containing the E domain.<span
style="mso-spacerun: yes">  </span>If the fibrin polymer has been cross-linked,
then two D domain-containing end fragments from different fibrin molecules will
be cross-linked together (see Figure 3, previous page).<span
style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>The
equilibrium between clot formation and degradation is a sensitive one that must
be tightly regulated  a weak clot could result in a haemorrhage, while a
strong could lead to thrombosis and blockage.<span style="mso-spacerun: yes"> 
</span>Various proteins can bind fibrin and<span style='mso-bidi-font-size:
14.0pt'> regulate the amount of clotting, cross-linking, and fibrinolysis</span>.<span
style="mso-spacerun: yes">  </span>These include:</p>

<h4><b>Clotting<o:p></o:p></b></h4>

<p class=MsoNormal style='margin-left:46.2pt;text-align:justify;text-indent:
-17.85pt;mso-list:l0 level1 lfo3;tab-stops:list 46.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]>Fibrin can bind thrombin at a separate, non-substrate
site in order to limit its diffusion and, therefore, its ability to propagate
clotting.</p>

<p class=MsoNormal style='margin-left:46.2pt;text-align:justify;text-indent:
-17.85pt;mso-list:l0 level1 lfo3;tab-stops:list 46.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]>Fibrin can bind anti-thrombin I, down-regulating the
amount of thrombin in clotting blood.</p>

<h4><b>Cross-linking<o:p></o:p></b></h4>

<p class=MsoNormal style='margin-left:46.2pt;text-align:justify;text-indent:
-17.85pt;mso-list:l2 level1 lfo4;tab-stops:list 46.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]>Fibrin can bind Factor XIII and regulate its activation
to Factor XIIIa, thereby suppressing fibrin polymer cross-linking.</p>

<h4><b>Fibrinolysis<o:p></o:p></b></h4>

<p class=MsoNormal style='margin-left:46.2pt;text-align:justify;text-indent:
-17.85pt;mso-list:l2 level1 lfo4;tab-stops:list 46.35pt'><![if !supportLists]><span
style='font-size:8.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]>Fibrin can bind <span style='font-family:Symbol'>a</span>2-anti-plasmin,
plasminogen activator inhibitor-2, and plasminogen to <span style='mso-bidi-font-size:
14.0pt'>regulate the initiation and propagation of fibrinolysis.</span></p>

<p class=MsoBodyTextIndent style='text-indent:0cm'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h2 align=center style='text-align:center'><span style='font-size:16.0pt;
mso-bidi-font-size:14.0pt;font-style:normal'>Next:<span style="mso-spacerun:
yes">  </span><a href="Page3.htm" title="Page 3">Fibrin and Cancer</a><o:p></o:p></span></h2>

<h2 align=center style='text-align:center'><span style='font-size:16.0pt;
mso-bidi-font-size:14.0pt;font-style:normal'>Previous:<span
style="mso-spacerun: yes">  </span><a href="Page1.htm" title="Page 1">Fibrinogen,
Finishing the Coagulation Cascade</a></span><span style='font-style:normal'><o:p></o:p></span></h2>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

</div>

</body>

</html>
